The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain

Phase 2

Completed

• Conditions: Neuropathic Pain

• Registration Number: NCT00376454
• Lead Sponsor: GlaxoSmithKline

Brief Summary

The purpose of this study was to determine the analgesic effect of GW493838 in patients with post-herpetic neuralgia or peripheral nerve injury caused by trauma or surgery.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-11
• Primary Completion: 2003-06
• Study Completion: 2003-06
• Study First Submitted: 2006-09-13
• Study First Submitted QC: 2006-09-13
• Study First Posted: 2006-09-14
• Status Verified: 2013-02
• Last Update Submitted: 2013-02-11
• Last Update Posted: 2013-02-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 113

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Pain intensity

Secondary Outcome Measures

Name	Time	Method
Safety Pain relief Global Impression of Change Pain quality Evoked pain intensity Area of allodynia Onset of effect Responder rate Rescue medication pharmacokinetics

Trial Locations

Locations (1)

GSK Clinical Trials Call Center; 🇺🇸 Madison, Wisconsin, United States